Rebimastat

Drug Profile

Rebimastat

Alternative Names: BMS 275291; D 2163

Latest Information Update: 24 Sep 2007

Price : $50

At a glance

  • Originator Celltech Group
  • Developer Bristol-Myers Squibb
  • Class Antineoplastics; Hydantoins; Small molecules
  • Mechanism of Action Metalloprotease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Breast cancer; Cancer; Kaposi's sarcoma; Non-small cell lung cancer; Prostate cancer

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 02 Sep 2004 A study has been added to the Cancer therapeutic trials section
  • 17 Sep 2003 A clinical study has been added to the adverse events section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top